Treatment with paclitaxel inhibits the proliferation and metastatic potential of breast cancer cells by inducing the expression of KLF17 and suppressing the expression of snail, PARK7, and ID1, which results in the inhibition of epithelial-mesenchymal transition [133]. Here, PARK7 is linked to breast cancer.